866-997-4948(US-Canada Toll Free)

Metastatic Hepatocellular Carcinoma (HCC) Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 47 Pages


Metastatic Hepatocellular Carcinoma (HCC) Pipeline Review, H2 2012

Global Markets Directs, 'Metastatic Hepatocellular Carcinoma (HCC) Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC). Metastatic Hepatocellular Carcinoma (HCC) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Hepatocellular Carcinoma (HCC).
  • A review of the Metastatic Hepatocellular Carcinoma (HCC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Hepatocellular Carcinoma (HCC) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Hepatocellular Carcinoma (HCC) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) 8
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics under Development by Companies 10
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Products under Development by Companies 14
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Products under Investigation by Universities/Institutes 15
Companies Involved in Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Development 16
F. Hoffmann-La Roche Ltd. 16
Novartis AG 17
Chugai Pharmaceutical Co. Ltd 18
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
RG-7686 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Sorafenib1 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Sorafenib4 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Bevacizumab + Sorafenib - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
GC33 + Nexavar - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Gemcitabine + Docetaxel - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Sorafenib + Everolimus - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
tegafur + gimeracil + oteracil potassium - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
tegafur + gimeracil + oteracil potassium - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
S-1 + Interferon Alpha - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Sorafenib + Radiation Therapy - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Sorafenib + Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Lenalidomide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
pasireotide + everolimus - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
temsirolimus - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Drug Profile Updates 42
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Discontinued Products 43
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Dormant Products 44
Metastatic Hepatocellular Carcinoma (HCC) Product Development Milestones 45
Featured News & Press Releases 45
Apr 13, 2010: Endo, Penwest Enter Into Agreement With Barr To Settle Patent Litigation Over Opana ER 45

Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Table


Number of Products Under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2012 8
Products under Development for Metastatic Hepatocellular Carcinoma (HCC) Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
F. Hoffmann-La Roche Ltd., H2 2012 16
Novartis AG, H2 2012 17
Chugai Pharmaceutical Co. Ltd, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Drug Profile Updates 42
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Discontinued Products 43
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Dormant Products 44

List of Chart


Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2012 8
Products under Development for Metastatic Hepatocellular Carcinoma (HCC) Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *